A Randomized, Double-Blind, Double-Dummy, Single-Dose, Crossover Trial Evaluating the Efficacy and Safety Profiles of Two Dose Levels (12 and 24 μg) of Formoterol-HFA (pMDI) vs. Those of a Dose Level (24 μg) of Formoterol-DPI (Foradil®/Aerolizer) and of Placebo (pMDI or Aerolizer) in Moderate to Severe Asthmatic Patients

Publisher: Karger

E-ISSN: 1423-0356|72|1|13-19

ISSN: 0025-7931

Source: Respiration, Vol.72, Iss.1, 2005-05, pp. : 13-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content